Paul Nguyen
@DrPaulNguyen
Followers
2K
Following
534
Media
13
Statuses
100
Prostate Cancer radiation oncologist at @DanaFarber and @BrighamWomens. @Harvardradonc Associate Program Director. @NRGonc GU Chair
Boston, MA
Joined September 2012
Practice-informing but not pivotal by @DrPaulNguyen: ENZARAD Ph III: ADT+RT ± enzalutamide for high-risk localized PCa. MFS HR 0.88 (95% CI 0.67-1.15); p=0.34. PSA PFS 0.78 (0.61, 0.99), p=0.044. #ESMO25 #ProstateCancer @myESMO @Annals_Oncology @OncLive @OncoAlert @DanaFarber
2
12
25
🚨ENZARAD at #ESMO25 presented by @DrPaulNguyen No improvement in MFS or OS with the addition of enzalutamide to high dose radiotherapy + 2y ADT in high risk #prostatecancer Possible benefit in cN1 pts or pts treated with pelvic RT.
3
43
86
Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science
4
43
82
Great talk from @DrPaulNguyen — enzalutamide did not improve MFS for high risk localized #prostatecancer in #ENZARAD. #ESMO25 @myESMO #ESMOAmbassadors @OncoAlert
Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science
4
10
24
Excellent presentation by @DrPaulNguyen on EnzaRad. Heterogenous population but N1/Stampede high risk group appears to benefit. #ESMO25 @myESMO @OncoAlert
2
14
39
Congratulations @weeloonong and thank you for spearheading this wonderful cross-continent collaboration between @NRGonc and @TROGfightcancer to define the role of SBRT in high risk prostate cancer! More collabs to come!
Not possible without the collaboration between @NRGonc and @TROGFightCancer, support from @KHoffmanMD @DrPaulNguyen and contributions of the many Australian CI @jeremymillar @theresekang_
@Niluja5 @DavePryorRO @damien_bolton and many others not on X! 🙏🙏
0
0
3
I’m so grateful to all of the investigators and patients within @NRGonc and support from @theNCI @Veracyte @JNJInnovation and co-leadership from Dr Oliver Sartor and the deeply missed visionary @felixfengmd to get this trial accrued two years ahead of schedule!
PRESS RELEASE: NRG Oncology PREDICT-RT Study Completes Patient Accrual, Tests Individualized Concurrent Therapy and Radiation for High-Risk Prostate Cancer - Read the Release: https://t.co/LzKA5JNnjB
@DrPaulNguyen @Veracyte
4
4
40
PRESS RELEASE: NRG Oncology PREDICT-RT Study Completes Patient Accrual, Tests Individualized Concurrent Therapy and Radiation for High-Risk Prostate Cancer - Read the Release: https://t.co/LzKA5JNnjB
@DrPaulNguyen @Veracyte
1
11
21
📢Special day: Literally Dr. Anthony Zietman's Last Day in #radonc clinic😳🥳😔 After 3️⃣9️⃣ years of service🙏🙏🙏 Handing the torch 🔥(for the clinic space that is😉) to @sophia_kamran 😅 A loss for our field, but he is going out on top‼️⛰️ @sueyom
12
14
98
So grateful to @ASTRO_org CEO Dr Vivek Kavadi for an amazing talk to our #HROP faculty and residents!
It was an honor to have @ASTRO_org CEO, Dr. Vivek Kavadi, return to his alma mater @harvardmed & speak on his life/ career trajectory and vision to advance cancer care & our field of radiation oncology! #HROP #BeamOn
1
5
41
Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? @DrChoueiri @nlinmd @DrKarenKnudsen @DrPaulNguyen @APDicker @EdwinPosadasMD @DrKatePedersen @JoshLangMD @PamelaKunzMD @fumikochino
5
8
92
Hope to see everyone virtually at the 2025 @ASTRO_org Refresher Meeting this Wednesday-Friday for the latest updates in every disease site, econtouring sessions, and special radbio/physics talks from the comfort of your own home!!
Paul L. Nguyen, MD, MBA, FASTRO, Program Chair, shares why you should join him in participating in the 2025 Virtual Annual Refresher Course. Register now to get a comprehensive review of the best practices & emerging trends for the major disease sites! 📣 https://t.co/D4DOUqgNF8
1
4
29
Thank you so much @EChrisDee ! I was once the teacher but now I am so proud that you are the teacher leading so many peers and students to scientific discovery!
So proud of my mentor ever since med school @DrPaulNguyen #FASCO AND #FASTRO 🤩🤩 A true example of dedication, service, brilliance, humility, and generosity 🙏
0
1
11
So happy to continue this wonderful @HarvardRadOnc tradition of “ResGiving” for the 8th year and thank you @LishSmartMD for the amazing venue and @TracyABalboni & Dr Jen Wo for awesome drinks & desserts!
Thank you @DrPaulNguyen for the annual Popeyes and @TracyABalboni for homemade pies ☺️ 🙏
0
2
30
📜 In @NatRevUrol, we review #prostate #cancer racial disparities in the #USA and #UK 👉 Insights from both settings may contribute to equitable care globally 🙏 Thank you to our #international, #diverse, and truly #multidisciplinary team 🔗 https://t.co/OWI3q9NY4c
@Nature
2
9
36
Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa
26
161
357
Let's spread the word! @DrSpratticus @AmarUKishan @PBlanchardMD @HimanshuNagarMD @ChadTangMD @_ShankarSiva @PaulSargos @DrPaulNguyen @AudLi @dr_vesi @DrStanLiu @felixfengmd @ASTRO_Chair @DrHowardSandler @NehaVapiwala
Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa
0
11
35
Standing ovation #ASTRO24 for @felixfengmd, recognised for his outstanding mentorship in our field, and also to formally announce the Felix Feng Clinician Scientist Development award
2
29
135
NRG GU-009/PREDICT-RT Intensification Arms completed accrual yesterday, 2 years ahead of schedule! Thank you @NRGonc GU investigators and patients and let’s keep up the great momentum to accrue the De-Intensification Arms (24 vs 12 mos ADT) over the next year!
4
20
113
